AB Sciences masitinib receives orphan drug status from Swissmedic to treat amyotrophic lateral sclerosis

AB Science SA , a pharmaceutical company, announces that masitinib has been granted orphan drug status (ODS) by the Swiss Agency for Therapeutic Products (Swissmedic) for the treatment of patients with amyotrophic lateral sclerosis (ALS). As a reminder, masitinib has previously received ODS for ALS from the US Food and Drug Administration (FDA) and from the European Medicines Agency (EMA). This designation provides the sponsor with a series of incentives, including: the possibility of a simplified authorization procedure (Art.13) by Swissmedic; fee waivers, and extended document protection period of 15 years. Orphan drug designation in Switzerland is given to compounds that are developed for the treatment of a life-threatening or chronically disabling disease that affects no more than 5 out of 10,000 persons in Switzerland, or its active substance has been recognized as an important medicinal product for rare diseases in another country with equivalent medicinal product control as stipulated in Art. 13 TPA. Professor Olivier Hermine, president of the scientific committee of AB Science and member of the Acad

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!